SLC5A2 and diabetic ketoacidosis: The use of metformin and sodium/glucose cotransporter 2 (SGLT-2) inhibitors in diabetic patients with COVID-19 should be discontinued due to the risk of diabetic ketoacidosis and hyperglycemic diabetic ketoacidosis.